Protagonist Therapeutics Inc. (PTGX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Protagonist Therapeutics Inc. (PTGX:NASDAQ), powered by AI.

Current Price
$98.37
Consensus Target
$113.33 (+15.2%)
Analyst Coverage
12 analysts
P/E Ratio
22.0
Market Cap
6.1B
Sector
Healthcare
What is the Protagonist Therapeutics Inc. stock price forecast?

12 analysts have a consensus target of $113.33, representing +15.2% upside from the current price.

What is Protagonist Therapeutics Inc. insider trading activity?

View the latest insider trading data for Protagonist Therapeutics Inc. on Alpha Lenz.

What is Protagonist Therapeutics Inc.'s P/E ratio?

Protagonist Therapeutics Inc.'s P/E ratio is 22.0.

Protagonist Therapeutics Inc.

NASDAQ · PTGX
$98.37
Ask about Protagonist Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Protagonist Therapeutics Inc. trades at a P/E of 22.0 (fair value) with strong ROE of 54.4%. 3Y revenue CAGR of 151.4% highlights clear growth momentum.

Ask for details

Company Overview

Protagonist Therapeutics Inc. is a biopharmaceutical company dedicated to the discovery and development of peptide-based therapeutics. These therapeutics are designed to address significant unmet medical needs, focusing on diseases that involve critical biological pathways regulated by peptides and proteins. Utilizing a proprietary technology platform, Protagonist Therapeutics develops solutions for conditions such as inflammatory bowel disease, myeloproliferative neoplasms, and other serious health disorders. The company’s innovative approach aims to combine the efficacy and safety of peptide drugs with novel mechanisms of action, providing targeted treatments that can potentially improve patient outcomes. Located in Newark, California, Protagonist Therapeutics plays a vital role in the biotechnology industry, contributing to advances in medical treatments and the broader healthcare sector. Its research and development efforts are significant, offering potential new therapies that could positively impact both patients’ lives and healthcare practices.

CEODr. Dinesh V. Patel Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees130

Company Statistics

FY 2024

Profile

$6.06BMarket Cap
$434.43MRevenue
0.00Shares Out
130Employees

Margins

N/AGross
58.87%EBITDA
58.20%Operating
64.32%Pre-Tax
63.34%Net

Valuation

22.01P/E
8.97P/B
13.94EV/Sales
23.34EV/EBITDA
33.13P/FCF

Growth (CAGR)

151.35%Rev 3Yr
351.71%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

49.91%ROA
54.39%ROE
45.86%ROIC

Financial Health

$97.25MCash & Cash Equivalents
$-27.82MNet Debt
10.28%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Protagonist Therapeutics Inc. (ticker: PTGX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 130 employees. Market cap is $6.1B.

The current price is $98.37 with a P/E ratio of 22.01x and P/B of 8.97x.

ROE is 54.39% and operating margin is 58.20%. Annual revenue is $434M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Protagonist Therapeutics Inc. (Healthcare) Stock Forecast & Analysis $98.37 | Alpha Lenz